GRF.MC - Grifols, S.A.

MCE - MCE Precio demorado. Divisa en EUR

Grifols, S.A.

Avinguda de la Generalitat, 152
Parc empresarial Can Sant Joan Sant Cugat del Valles
Barcelona 08174
Spain
34 93 571 00 00
http://www.grifols.com

SectorHealthcare
SectorDrug Manufacturers—General
Empleados a tiempo completo22.000

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Raimon Grifols RouraCo-CEO & Exec. DirectorN/AN/A1964
Mr. Tomás Dagá GelabertVice Sec. & External DirectorN/AN/A1956
Mr. Víctor Grífols DeuCo-CEO & Exec. DirectorN/AN/A1977
Mr. Alfredo Arroyo GuerraCFO & VPN/AN/A1958
Mrs. Eva Bastida TubauCorp. VP and Director of Scientific & Medical AffairsN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2015 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Grifols, S.A. develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products. It offers plasma products, such as intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. has a technology collaboration agreement with Mondragon to jointly develop healthcare sector-related automation, robotics, and instrumentation, as well as other technologies and infrastructure. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Gobierno corporativo

El ISS Governance QualityScore de Grifols, S.A., a día 4 de octubre de 2019, es 2. Las puntuaciones base son Auditoría: 1; Tablero: 2; Derechos de los accionistas: 6; Compensación: 4.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.
Al usar Yahoo aceptas que Yahoo y sus socios puedan utilizar cookies para personalización y otros fines